Mycophenolate mofetil and tacrolimus: New therapeutic options in neuroimmunological diseases

Muscle and Nerve

Volumn 34, Issue 3, 2006, Pages 284-291

  Schneider Gold, Christiane ^a   Hartung, Hans Peter ^b   Gold, Ralf ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

FK 506; Immunosuppression; Myasthenia gravis; Mycophenolate mofetil; Neurological autoimmune diseases; Tacrolimus

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CREATINE KINASE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PREDNISONE; TACROLIMUS;

ABDOMINAL PAIN; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ALOPECIA; ANEMIA; AUTOIMMUNE DISEASE; CARDIOMYOPATHY; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CREATINE KINASE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DERMATOMYOSITIS; DIABETES MELLITUS; DIARRHEA; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; GASTRITIS; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERPLASIA; HEMOLYTIC ANEMIA; HIRSUTISM; HUMAN; HYPERBILIRUBINEMIA; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPOMAGNESEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY CANCER; LEUKOPENIA; LUNG CANCER; LYMPHOCYTOPENIA; LYMPHOMA; MYASTHENIA GRAVIS; MYOSITIS; NEPHROTOXICITY; NEUROIMMUNOLOGY; NEUROTOXICITY; OPPORTUNISTIC INFECTION; PNEUMONIA; POLYMYOSITIS; POLYNEUROPATHY; PRIORITY JOURNAL; PRURITUS; PSORIASIS; RESPIRATORY FAILURE; REVIEW; SEPSIS; SEPTICEMIA; SKIN CANCER; SKIN TOXICITY; THROMBOSIS; TREMOR; URINARY TRACT DISEASE; UROGENITAL TRACT INFECTION;

AUTOIMMUNE DISEASES OF THE NERVOUS SYSTEM; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYCOPHENOLIC ACID; NEUROIMMUNOMODULATION; TACROLIMUS;

EID: 33748030791     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.20543     Document Type: Review

References (54)

1. Ahlmen J, Andersen O, Hallgren G, Peilot B. Positive effects of tacrolimus in a case of CIDP. Transplant Proc 1998;30: 4194.
2. Ahrens N, Salama A, Haas J. Mycophenolate-mofetil in the treatment of refractory multiple sclerosis. J Neurol 2001;248: 713-714.
3. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000;47:85-118.
4. Benedetti L, Grandis M, Nobbio L, Beronio A, Ghiglione E, Manzino M, et al. Mycophenolate mofetil in dysimmune neuropathies: a preliminary study. Muscle Nerve 2004;29:748-749.
5. Besinger UA, Toyka KV, Homberg M, Heiniger K, Hohlfeld R, Fateh-Moghadam A. Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity. Neurology 1983;33:1316-1321.
6. Blaheta RA, Leckel K, Wittig B, Zenker D, Oppermann E, Harder S, et al. Inhibition of endothelial receptor expression and T-cell ligand activity by mycophenolate mofetil. Transplant Immunol 1998;6:251-259.
7. Boukriche Y, Brugiere O, Castier Y, Stocco J, Mal H, Fournier M. Severe axonal polyneuropathy after a FK 506 overdosage in a lung transplant patient. Transplantation 2001;15:1849-1850.
8. Budde K, Glander P, Bauer S, Braun K, Waiser J, Fritsche L, et al. Pharmacodynamic monitoring of mycophenolate mofetil. Clin Chem Lab Med 2000;38:1213-1216.
9. Chaudry V, Cornblath DR, Griffin JW, O'Brien R, Drachman DB. Mycophenolate mofetil-a safe and promising immunosuppressant in neuromuscular diseases. Neurology 2001;56: 94-96.
10. Ciafaloni E, Massey JM, Tucker-Lipscombe B, Sanders DB. Mycophenolate mofetil for myasthenia gravis: an open-label pilot study. Neurology 2001;56:97-99.
11. Cohn RG, Mirkovich A, Dunlap B, Burton P, Chiu SH, Eugui E, et al. Mycophenolic acid increases apoptosis, lysosomes and lipid droplets in human lymphoid and monocytic cell lines. Transplantation 1999;68:411-418.
12. Davies TH, Ning YM, Sanchez ER. Differential control of glucocorticoid receptor hormone-binding function by tetratricopeptide (TPR) proteins and the immunosuppressive ligand FK 506. Biochemistry 2005;44:2030-2038.
13. Dawson TM, Steiner JP, Dawson VL, Dinerman JL, Uhl GR, Snyder SH. Immunosuppressant FK 506 enhances phosphorylation of nitric oxide synthase and protects against glutamate neurotoxivity. Proc Natl Acad Sci USA 1993;90:9741-9743.
14. Durez P, Apelboom, T, Pira C, Stordeur P, Vray B, Goldman M. Antiinflammatory properties of mycophenolate mofetil in murine endotoxemia: inhibition of TNF-alpha and upregulation of IL-10 release. Int J Immunopharmacol 1999;21:581-587.
15. Enk AH, Knop J. Treatment of pemphigus vulgaris with mycophenolate mofetil. Lancet 1997;350:494.
16. Epinette WW, Parker CM, Jones EL, Greist MC. Mycophenolic acid for psoriasis. A review of pharmacology, long-term efficacy, and safety. J Am Acad Dermatol 1987;17:962-971.
17. Eugui EM, Mirkovich A, Allison AC. Lymphocyte-selective antiproliferative and immunosuppressive effects of mycophenolic acid in mice. Scand J Immunol 1991;33:175-183.
18. European Mycophenolate Mofetil Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporine and corticosteroids for prevention of acute rejection. Lancet 1995;345:1321-1325.
19. Fellermann K, Tanko Z, Herrlinger KR, Witthoeft T, Homann N, Bruening A, et al. Response to refractory colitis to intravenous or oral tacrolimus (FK 506). Inflamm Bowel Dis 2002; 8:317-324.
20. Gelber AC, Nousari HC, Wigley FM. Mycophenolate mofetil in the treatment of severe skin manifestations of dermatomyositis: a series of 4 cases. J Rheumatol 2000;27:1542-1545.
21. Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, et al. Mycophenolate mofetil or intravenous cyclosphosphamide for lupus nephritis. N Engl J Med 2005;353:2219-2228.
22. Goldblum R. Treatment of rheumatoid arthritis with mycophenolate mofetil. Clin Exp Rheumatol 1993;11(suppl 8): S117-S119.
23. Gorson KC, Amato AA, Ropper AH. Efficacy of mycophenolate mofetil in patients with chronic immune demyelinating polyneuropathy. Neurology 2004;63:715-717.
24. Gummert JF, Ikonen T, Morris RE. Newer immunosuppressive drugs. A review. J Am Soc Nephrol 1999;10:1366-1380.
25. Hauser RA, Malek AR, Rosen R. Successful treatment of a patient with severe refractory myasthenia gravis using mycophenolate mofetil. Neurology 1998;51:912-913.
26. Kawaguchi N, Yoshiyama Y, Nemoto Y, Munakata S, Fukutake T, Hattori T. Low-dose tacrolimus treatment in thymectomised and steroid-dependent myasthenia gravis. Curr Med Res Opin 2004;20:1269-1273.
27. Kino T, Inamura N, Sakai F, Nakahara K, Goto T, Okuhara M, et al. Effect of FK 506 on human mixed lymphocyte reaction in vitro. Transplant Proc 1987;19:36-39.
28. Konishi T, Yoshiyama Y, Takamori M, Yagi K, Mukai E, Daida T, et al. Clinical study of FK 506 in patients with myasthenia gravis. Muscle Nerve 2003;28:570-574.
29. Konishi T, Yoshiyama Y, Takamori M, Saida T. Long-term treatment of generalised myasthenia gravis with FK 506 (tacrolimus). J Neurol Neurosurg Psychiatry 2005;76:448-450.
30. Larkin G, Lightman S. Mycophenolate mofetil. A useful immunosuppressive in inflammatory eye disease. Ophthalmology 1999;106:370-374.
31. Lhotta K, Wurzner R, Rosenkranz AR, Beer R, Rudisch A, Neumair F, et al. Cerebral vasculitis in a patient with hereditary complete C4 deficiency and systemic lupus erythematosis. Lupus 2004;13:139-141.
32. Majithia V, Harisdangkul V. Mycophenolate mofetil (Cell-Cept): an alternative therapy for autoimmune inflammatory myopathy. Rheumatology 2005;44:386-389.
33. Margreiter R. Efficacy and safety of tacrolimus compared with cyclosporine microemulsion in renal transplantation. A randomised multicentre study. European tacrolimus vs. cyclosporine microemulsion renal transplantation study group. Lancet 2002;359:741-746.
34. Mastaglia FL, Garlepp MJ, Phillips BA, Zilko PJ. Inflammatory myopathies: clinical diagnostic and therapeutic aspects. Muscle Nerve 2003;27:407-425.
35. Meriggioli MN, Ciafaloni E, Al-Hayk KA, Rowin J, Tucker-Lipscom B, Massey JM, et al. Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety and tolerability. Neurology 2003;61:1438-1440.
36. Meriggioli MN, Rowin J, Richman JG, Leurgans, S. Mycophenolate mofetil for myasthenia gravis: a double-blind, placebo-controlled pilot study. Ann NY Acad Sci 2003;998:494-499.
37. Mowzoon N, Sussman A, Bradley WG. Mycophenolate (Cell-Cept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis. J Neurol Sci 2001;185:119-122.
38. Neurath MF, Wanitschke R, Peters M, Krummenauer F, Meyer zum Büschenfelde KH, Schlaak F. Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn's disease. Gut 1999;44:625-628.
39. Nowack R, Gôbel U, Klooker P, Hergesell O, Andrassy K, van der Woude FJ. Mycophenolate mofetil for maintenance therapy of Wegener's granulomatosis and microscopic polyangiitis. A pilot study in 11 patients with renal involvement. J Am Soc Nephrol 1999;10:1965-1971.
40. Oddis CS, Sciurba FC, Elmagd KA, Starzl TE. Tacrolimus in refractory polymyosits with interstitial lung disease. Lancet 1999;353:1762-1763.
41. Orlandi V, Campieri C, Mosconi G, D'Arcangelo GL, Feliciangeli G, Scolari MP et al. Tacrolimus-associated myositis: a case-report in a renal transplant patient. Transplant Proc 2004;36:708-710.
42. Politt D, Heintz B, Floege J, Mertens PR. Tacrolimus- (FK 506) based immunosuppression in severe systemic lupus erythematosus. Clin Nephrol 2004;62:49-53.
43. Ponseti JM, Azem J, Fort JM, Lopez-Cano M, Vilallonga R, Buera M, et al. Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis. Neurology 2005;64:1641-1643.
44. Ponseti JM, Azem J, Fort JM, Codina A, Montoro JB, Armengol M. Benefits of FK 506 (tacrolimus) for residual, cyclosporine- and prednisone resistant myasthenia gravis: one year follow-up of an open-label study. Clin Neurol Neurosurg 2005;107:187-190.
45. Schneider C, Gold R, Reiners K, Toyka KV. Mycophenolate mofetil in the therapy of severe myasthenia gravis. Eur Neurol 2001;46:79-82.
46. Schneider C, Gold R, Schäfers M, Toyka KV. Mycophenolate mofetil in the therapy of polymyositis associated with a polyautoimmune syndrome. Muscle Nerve 2002;25:286-288.
47. Scott LJ, Mc Keage M, Kem SJ, Plosker GL. Tacrolimus. A further update of its use in the management of organ transplantation. Drugs 2003;63:1247-1297.
48. Shinojima Y, Gono T, Yamamoto K, Hoshi K, Matsuda M, Yoshida K, et al. Efficacy of tacrolimus in the treatment of polymyositis associated with myasthenia gravis. Clin Rheumatol 2004;23:262-265.
49. Wenzel J, Montag S, Wilsmann-Theis D, Gaffal E, Bieber T, Tuting T. Successful treatment of recalcitrant Wegener's granulomatosis of the skin with tacrolimus (Prograf). Br J Dermatol 2004;151:927-928.
50. Wilson JR, Conwit RA, Eidelman BH, Starzl T, Abu-Elmagd K. Sensorimotor neuropathy resembling CIDP in patients receiving FK 506. Muscle Nerve 1994;17:528-532.
51. Woodle ES, Fukisawa Corticosteroid Withdrawal Study Group. A prospective, randomized, multicenter, double-blind study of early corticosteroid cessation versus long-term maintenance of corticosteroid therapy with tacrolimus and mycophenolate mofetil in primary renal transplant recipients: one year report. Transplant Proc 2005;37:804-808.
52. Yamada A, Ohshima Y, Omata N, Yasumoti M, Mayumi M. Steroid-sparing effect of tacrolimus in a patients with juvenile dermatomyosits presenting poor bioavailability of cyclosporine A. Eur J Pediatr 2004;163:561-562.
53. Yoshida EM, Devonshire VA, Prout AJ. Remission of multiple sclerosis post liver transplantation. Can J Neurol Sci 2004;31: 539-541.
54. Yoshimasu T, Ohtani T, Sakamoto T, Oshima A, Furukawa F. Topical FK 506 therapy for facial erythematosus lesions of cutaneous lupus erythematosus and dermatomyositis. Eur J Dermatol 2002;12:387-388.